Repatha Month-by-Month: What to Expect in the First 3 Months

How fast does the LDL drop, and when does it level off?

Evolocumab is a monoclonal antibody that binds PCSK9, a protein that normally binds the LDL receptor on liver cells and promotes its degradation. Blocking that binding leaves more receptors free to clear LDL from the blood [1].

The effect arrives quickly. After a single dose, unbound PCSK9 was maximally suppressed by 4 hours, and maximum LDL-C reduction occurred by 2 weeks after a 140 mg dose and by 3 weeks after a 420 mg dose [1]. Trough drug levels approach steady state by 12 weeks [1].

The size of the drop in a statin-treated population comes from LAPLACE-2. In the label's account of that 12-week trial in 1,896 adults with hypercholesterolemia on a background statin, the LDL-C difference versus placebo was -71% with 140 mg every 2 weeks and -63% with 420 mg monthly; versus ezetimibe 10 mg the differences were -45% and -41% [1]. The published trial reported 66% to 75% (every 2 weeks) and 63% to 75% (monthly) reductions versus placebo at the mean of weeks 10 and 12, with on-treatment means of 33 to 49 mg/dL depending on statin intensity and regimen [3].

FOURIER, which enrolled 27,564 people with established atherosclerotic cardiovascular disease, showed the same pattern at scale: median LDL-C went from 92 mg/dL at baseline to 30 mg/dL at week 48, a 59% reduction versus placebo [4]. The label gives the between-group LDL-C difference as -63% at week 12 and -57% at week 72 [1].

Month 1: the first injection and the first lab

For adults at increased cardiovascular risk or with hypercholesterolemia, and for adults and children 10 years and older with HeFH, the labeled regimens are 140 mg every 2 weeks or 420 mg once monthly, injected under the skin into the abdomen, thigh or upper arm with site rotation [1]. The label specifies that a 420 mg dose is given as three consecutive 140 mg injections within 30 minutes [1].

For storage, the label says to keep the pen or syringe refrigerated at 2 to 8 C in the carton and not to freeze or shake it. It may be kept at room temperature (20 to 25 C) in the carton for up to 30 days, and the label allows 30 minutes to warm to room temperature before use [1]. Some presentations have dry natural rubber (latex) in the needle cover, and latex-free presentations exist [1].

The label says the LDL-lowering effect may be measured as early as 4 weeks after starting; with the monthly regimen, it says to measure just before the next dose [1].

Side-effect rates come from a 52-week placebo-controlled trial (Repatha 420 mg monthly, 599 people, versus 302 on placebo). Nasopharyngitis occurred in 10.5% versus 9.6%, upper respiratory tract infection 9.3% versus 6.3%, influenza 7.5% versus 6.3%, back pain 6.2% versus 5.6%, injection-site reactions 5.7% versus 5.0%, cough 4.5% versus 3.6%, urinary tract infection 4.5% versus 3.6%, sinusitis 4.2% versus 3.0%, headache 4.0% versus 3.6%, myalgia 4.0% versus 3.0% and dizziness 3.7% versus 2.6% [1]. Treatment discontinuation was 2.2% versus 1.0%, with myalgia the most frequent reason (0.3% versus 0%) [1].

Across eight pooled controlled trials, injection-site reactions were 3.2% versus 3.0% on placebo, mostly erythema, pain and bruising, with 0.1% discontinuing; hypersensitivity reactions were 5.1% versus 4.7% [1].

Month 2: steady state is still approaching

Trough drug levels approach steady state by about 12 weeks, so month 2 falls inside that window. The label says LDL-C can be measured from 4 weeks [1].

In the 115-patient observational study, 72% of patients were persistent with treatment, 5.2% had treatment-emergent adverse drug reactions, and no serious adverse events were reported over follow-up [2].

On statin co-use, 69% of FOURIER participants were on a high-intensity statin [4]. The label notes that about 20% lower Cmax and AUC of evolocumab were seen in adults on a high-intensity statin and calls that difference not clinically meaningful; the label has no drug interactions section [1].

Month 3: is it working?

In the real-world cohort, median LDL-C had fallen from 147 mg/dL to 53 mg/dL within the first 3 months, a 63.9% reduction, and median values remained below 45 mg/dL until the end of follow-up [2].

For one group, month 3 is also a dosing decision point. In homozygous familial hypercholesterolemia the label starts at 420 mg once monthly and allows an increase to 420 mg every 2 weeks if the response is not clinically meaningful by 12 weeks [1].

The first three months mainly show the LDL-C response. Evidence for cardiovascular outcomes comes from longer trials, including FOURIER, which had a median follow-up of 26 months in the label and 2.2 years in the publication [1][4]. In FOURIER, the primary composite of cardiovascular death, myocardial infarction, stroke, unstable angina hospitalization or coronary revascularization occurred in 1,344 people (9.8%) on evolocumab versus 1,563 (11.3%) on placebo, hazard ratio 0.85 (95% CI 0.79-0.92) [1][4]. The key secondary composite of cardiovascular death, myocardial infarction or stroke was 816 (5.9%) versus 1,013 (7.4%), hazard ratio 0.80 (95% CI 0.73-0.88) [4]. Cardiovascular death alone was 251 versus 240 (HR 1.05, 95% CI 0.88-1.25) and all-cause death 444 versus 426 (HR 1.04, 95% CI 0.91-1.19) [1].

VESALIUS-CV tested evolocumab in 12,257 people with atherosclerosis or diabetes and no previous myocardial infarction or stroke, over a median 4.6 years: 3-point MACE occurred in 336 (5-year Kaplan-Meier estimate 6.2%) versus 443 (8.0%), hazard ratio 0.75 (95% CI 0.65-0.86) [5].

Special groups: HoFH, statin intolerance and memory

Homozygous familial hypercholesterolemia is the clearest case of a smaller response. In TESLA Part B, 50 patients were randomized to evolocumab 420 mg or placebo every 4 weeks for 12 weeks, and 49 received study drug (33 evolocumab, 16 placebo). Evolocumab reduced ultracentrifugation LDL-C by 30.9% versus placebo at week 12 (95% CI -43.9% to -18.0%) [6].

People who cannot tolerate statins also had a large LDL-C response. GAUSS-3 enrolled 511 adults with a history of intolerance to two or more statins; 218 entered the randomized phase (145 evolocumab 420 mg monthly, 73 ezetimibe 10 mg), and at week 24 LDL-C changed by -52.8% with evolocumab versus -16.7% with ezetimibe [7].

Memory complaints are the other question people raise in the first months. In the EBBINGHAUS cognitive substudy of FOURIER, evolocumab was non-inferior to placebo on the spatial working memory strategy index of executive function (mean change -0.21 versus -0.29) over a median 19 months, with 1,204 patients followed; the label lists 1,974 patients enrolled and adds that evolocumab was also non-inferior on selected other cognitive domains [8][1].

Side effects and label warnings to know across the three months

Repatha has no boxed warning. Its only Warning and Precaution covers hypersensitivity reactions including angioedema; the label says to stop treatment and treat if serious symptoms occur [1]. A history of a serious hypersensitivity reaction to evolocumab or any excipient is a contraindication [1]. Angioedema and influenza-like illness have been reported after approval [1].

Antibodies to evolocumab developed in 0.3% of adults (48 of 17,992), none neutralizing, with no evidence of an effect on pharmacokinetics, response or safety [1].

In FOURIER, diabetes mellitus occurred in 8.8% versus 8.2%, and among 16,676 people without diabetes at baseline, new-onset diabetes occurred in 8.1% versus 7.7% [1].

Missed doses

The label describes these missed-dose rules: a dose missed by 7 days or less is given and the original schedule is resumed; on the every-2-week schedule, a dose more than 7 days late is deferred to the next scheduled dose; on the monthly schedule, the late dose starts a new schedule [1].